PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Expression profile, clinical significance, and biological function of insulin-like growth factor 2 messenger RNA-binding proteins in non-small cell lung cancer.

Abstract Insulin-like growth factor 2 messenger RNA-binding proteins have been described to associate with malignant process in many cancers. However, the role of insulin-like growth factor 2 messenger RNA-binding protein family has not been thoroughly elucidated in non-small cell lung cancer. This study was to investigate the expression profile, clinical significance, and biological function of insulin-like growth factor 2 messenger RNA-binding proteins family in non-small cell lung cancer. The expression levels of IGF2BP1-IGF2BP3 in tumor and adjacent normal tissues were determined, and association with clinicopathological features and overall survival was investigated by analyzing The Cancer Genome Atlas lung cancer database. Proliferation, migration, invasion assays, and flow-cytometry analysis were used to investigate the biological function in vitro. Insulin-like growth factor 2 messenger RNA-binding protein expression levels were significantly increased in non-small cell lung cancer compared to adjacent normal lung tissues. Chi-square test indicated that IGF2BP1 and IGF2BP3 expressions correlated with some meaningful clinical characteristics in non-small cell lung cancer. Kaplan-Meier analysis showed that high-level expression of IGF2BP1 or IGF2BP3 predicted poor overall survival in lung adenocarcinoma patients. Multivariate regression analysis showed that high level of IGF2BP3 was an independent risk factor for poor prognosis in lung adenocarcinoma patients (hazard ratio = 1.616, p = 0.017). In vitro, knockdown of IGF2BP3 inhibited lung adenocarcinoma cell proliferation by inducing cell cycle arrest and apoptosis, and undermined abilities of migration and invasion, and overexpression of IGF2BP3 could promote malignant phenotypes in lung adenocarcinoma cells. Our study revealed that expression of insulin-like growth factor 2 messenger RNA-binding proteins was widely upregulated and correlated with some certain clinicopathological features in non-small cell lung cancer. Especially, in insulin-like growth factor 2 messenger RNA-binding protein family, IGF2BP3 might play the most important role in tumor aggressiveness and prognosis in lung adenocarcinoma, and IGF2BP3 might serve as a potential therapeutic target and a novel prognostic biomarker in lung adenocarcinoma patients.
PMID
Related Publications

Targeting insulin-like growth factor-binding protein-3 by microRNA-125b promotes tumor invasion and poor outcomes in non-small-cell lung cancer.

Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1 is associated with tumor progression in patients with lung cancer.

Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer.

Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer.

Insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor formation and invasion and predicts poor prognosis in oral squamous cell carcinoma.

Authors

Mayor MeshTerms
Keywords

Insulin-like growth factor 2 messenger RNA-binding proteins

The Cancer Genome Atlas

non–small cell lung cancer

prognosis

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28381175
OWN - NLM
STAT- MEDLINE
DA  - 20170406
DCOM- 20170418
LR  - 20170418
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 4
DP  - 2017 Apr
TI  - Expression profile, clinical significance, and biological function of
      insulin-like growth factor 2 messenger RNA-binding proteins in non-small cell
      lung cancer.
PG  - 1010428317695928
LID - 10.1177/1010428317695928 [doi]
AB  - Insulin-like growth factor 2 messenger RNA-binding proteins have been described
      to associate with malignant process in many cancers. However, the role of
      insulin-like growth factor 2 messenger RNA-binding protein family has not been
      thoroughly elucidated in non-small cell lung cancer. This study was to
      investigate the expression profile, clinical significance, and biological
      function of insulin-like growth factor 2 messenger RNA-binding proteins family in
      non-small cell lung cancer. The expression levels of IGF2BP1-IGF2BP3 in tumor and
      adjacent normal tissues were determined, and association with clinicopathological
      features and overall survival was investigated by analyzing The Cancer Genome
      Atlas lung cancer database. Proliferation, migration, invasion assays, and
      flow-cytometry analysis were used to investigate the biological function in
      vitro. Insulin-like growth factor 2 messenger RNA-binding protein expression
      levels were significantly increased in non-small cell lung cancer compared to
      adjacent normal lung tissues. Chi-square test indicated that IGF2BP1 and IGF2BP3 
      expressions correlated with some meaningful clinical characteristics in non-small
      cell lung cancer. Kaplan-Meier analysis showed that high-level expression of
      IGF2BP1 or IGF2BP3 predicted poor overall survival in lung adenocarcinoma
      patients. Multivariate regression analysis showed that high level of IGF2BP3 was 
      an independent risk factor for poor prognosis in lung adenocarcinoma patients
      (hazard ratio = 1.616, p = 0.017). In vitro, knockdown of IGF2BP3 inhibited lung 
      adenocarcinoma cell proliferation by inducing cell cycle arrest and apoptosis,
      and undermined abilities of migration and invasion, and overexpression of IGF2BP3
      could promote malignant phenotypes in lung adenocarcinoma cells. Our study
      revealed that expression of insulin-like growth factor 2 messenger RNA-binding
      proteins was widely upregulated and correlated with some certain
      clinicopathological features in non-small cell lung cancer. Especially, in
      insulin-like growth factor 2 messenger RNA-binding protein family, IGF2BP3 might 
      play the most important role in tumor aggressiveness and prognosis in lung
      adenocarcinoma, and IGF2BP3 might serve as a potential therapeutic target and a
      novel prognostic biomarker in lung adenocarcinoma patients.
FAU - Shi, Run
AU  - Shi R
AD  - 1 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer
      Institute of Jiangsu Province, Nanjing, China.
AD  - 2 Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer
      Hospital, Nanjing, China.
AD  - 3 The Fourth Clinical College of Nanjing Medical University, Nanjing, China.
FAU - Yu, Xinnian
AU  - Yu X
AD  - 4 Department of Medical Oncology, Nanjing Medical University Affiliated Cancer
      Hospital, Nanjing, China.
FAU - Wang, Yajing
AU  - Wang Y
AD  - 5 The First Clinical College of Nanjing Medical University, Nanjing, China.
FAU - Sun, Jing
AU  - Sun J
AD  - 5 The First Clinical College of Nanjing Medical University, Nanjing, China.
FAU - Sun, Qi
AU  - Sun Q
AD  - 6 Department of Cardiothoracic Surgery, Jinling Hospital, Southern Medical
      University, Nanjing, China.
FAU - Xia, Wenjie
AU  - Xia W
AD  - 1 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer
      Institute of Jiangsu Province, Nanjing, China.
AD  - 2 Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer
      Hospital, Nanjing, China.
AD  - 3 The Fourth Clinical College of Nanjing Medical University, Nanjing, China.
FAU - Dong, Gaochao
AU  - Dong G
AD  - 1 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer
      Institute of Jiangsu Province, Nanjing, China.
FAU - Wang, Anpeng
AU  - Wang A
AD  - 1 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer
      Institute of Jiangsu Province, Nanjing, China.
AD  - 2 Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer
      Hospital, Nanjing, China.
AD  - 3 The Fourth Clinical College of Nanjing Medical University, Nanjing, China.
FAU - Gao, Zhaojia
AU  - Gao Z
AD  - 3 The Fourth Clinical College of Nanjing Medical University, Nanjing, China.
FAU - Jiang, Feng
AU  - Jiang F
AD  - 1 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer
      Institute of Jiangsu Province, Nanjing, China.
AD  - 2 Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer
      Hospital, Nanjing, China.
FAU - Xu, Lin
AU  - Xu L
AD  - 1 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer
      Institute of Jiangsu Province, Nanjing, China.
AD  - 2 Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer
      Hospital, Nanjing, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (IMP-1 protein, human)
RN  - 0 (IMP3 protein, human)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Apoptosis
MH  - Carcinoma, Non-Small-Cell Lung/*pathology
MH  - Cell Cycle Checkpoints
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*pathology
MH  - Male
MH  - Middle Aged
MH  - RNA-Binding Proteins/*physiology
OTO - NOTNLM
OT  - Insulin-like growth factor 2 messenger RNA-binding proteins
OT  - The Cancer Genome Atlas
OT  - non-small cell lung cancer
OT  - prognosis
EDAT- 2017/04/07 06:00
MHDA- 2017/04/19 06:00
CRDT- 2017/04/07 06:00
AID - 10.1177/1010428317695928 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Apr;39(4):1010428317695928. doi: 10.1177/1010428317695928.